

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549  
FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 1, 2002

DELCATH SYSTEMS, INC.  
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	001-16133 (Commission File Number)	06-1245881 (IRS Employer Identification No.)
---	--	--

1100 Summer Street, Stamford, Connecticut 06905  
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (203) 323-8668

N/A  
(Former name or former address, if changed since last report)

5. Other Events and Regulation FD Disclosure

On October 1, 2002, Delcath Systems, Inc. (the "Company") issued a press release announcing that its board of directors approved a stock repurchase program whereby the Company is authorized to repurchase a portion of its common stock. The Company's press release dated October 1, 2002 is incorporated herein by reference and filed as an exhibit hereto.

Item 7. Financial Statements and Exhibits

- (a) Not applicable
- (b) Not applicable
- (c) Exhibits

Exhibit No.	Description
99	Press Release dated October 1, 2002 of Delcath Systems, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DELCATH SYSTEMS, INC.

By: /s/ M. S. KOLY

-----  
M. S. Koly  
President and Chief Executive Officer

Date: October 2, 2002

EXHIBIT INDEX

Exhibit No.	Description
99	Press Release dated October 1, 2002 of Delcath Systems, Inc.

Contact:

M.S. Koly  
Chief Executive Officer  
Delcath Systems, Inc.  
203/323-8668  
www.delcath.com

Thomas Redington  
Redington, Inc  
203/222-7399  
212/926-1733  
www.redingtoninc.com

DELCATH APPROVES STOCK REPURCHASE PROGRAM

STAMFORD, CT OCT. 1 - Delcath Systems, Inc. (Nasdaq: DCTH) today announced that its board of directors approved a stock repurchase program whereby the company is authorized to repurchase a portion of its common stock.

The board approved the repurchase by the company of up to 7 percent of its outstanding common stock at such times, at such prices and on such other terms as the president and chief executive officer approves. Under the board's authorization, the company is not obligated to repurchase any shares. Certain of the directors of the company have also indicated that they may purchase additional shares for their own account. Any purchases the company or its directors may make will depend on market conditions.

Delcath's common stock is listed on the Nasdaq Small Cap Market and the Boston Stock Exchange under the symbols DCTH and DCT, respectively.

Delcath, a development-stage company, is in the business of developing and marketing a proprietary drug delivery system capable of introducing, and removing, high-dose chemotherapy agents to a diseased organ system while greatly inhibiting their entry into the general circulatory system.

# # #

This release contains "forward-looking statements" based on current expectations but involving known and unknown risks and uncertainties. Actual results or achievements may be materially different from those expressed or implied. Delcath plans and objectives are based on assumptions involving judgments with respect to future economic, competitive and market conditions, its ability to consummate, and the

timing of, acquisitions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond its control. Therefore, there can be no assurance than any forward-looking statement will prove to be accurate.

10/1/02